CIK 0001133869 · Non-accelerated filer<br>Smaller reporting company
CAPRICOR THERAPEUTICS, INC.
Sign in to watch- Ticker
- CAPR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (310) 358-3200
- Business address
- 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO, CA, 92121
- Former names
- Nile Therapeutics, Inc., SMI PRODUCTS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 97 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-18 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (Right to Buy) | −3,000 | 0 | ||
| 2026-05-13 | Litvack Frank Director | Option exercise | +3,937 | $1.39 | $5K | 133,776 |
| 2026-05-13 | Litvack Frank Director | Option exercise · Stock Option (Right to Buy) | −3,937 | 0 | ||
| 2026-05-01 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +25,000 | $3.18 | $80K | 33,223 |
| 2026-05-01 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −25,000 | $31.70 | $793K | 8,223 |
| 2026-05-01 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,000 | 116,980 | ||
| 2026-05-01 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise 10b5-1 | +25,000 | $3.18 | $80K | 55,547 |
| 2026-05-01 | Krasney Karen EVP, GENERAL COUNSEL | Sale 10b5-1 | −25,000 | $31.70 | $793K | 30,547 |
| 2026-05-01 | Krasney Karen EVP, GENERAL COUNSEL | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,000 | 56,261 | ||
| 2026-04-02 | Sabar Karimah Es Director | Option exercise 10b5-1 | +7,529 | $3.18 | $24K | 7,529 |
| 2026-04-02 | Sabar Karimah Es Director | Sale 10b5-1 | −7,529 | $32.00 | $241K | 0 |
| 2026-04-02 | Sabar Karimah Es Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,529 | 161 | ||
| 2026-04-01 | Sabar Karimah Es Director | Option exercise 10b5-1 | +53,735 | $4.86 | $261K | 53,735 |
| 2026-04-01 | Sabar Karimah Es Director | Sale 10b5-1 | −53,735 | $31.03 | $1.7M | 0 |
| 2026-04-01 | Sabar Karimah Es Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −53,735 | 0 | ||
| 2026-03-31 | Sabar Karimah Es Director | Option exercise 10b5-1 | +61,265 | $4.86 | $298K | 61,265 |
| 2026-03-31 | Sabar Karimah Es Director | Sale 10b5-1 | −61,265 | $30.17 | $1.8M | 0 |
| 2026-03-31 | Sabar Karimah Es Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −61,265 | 53,735 | ||
| 2026-03-31 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +25,000 | $3.18 | $80K | 33,223 |
| 2026-03-31 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −25,000 | $30.13 | $753K | 8,223 |
Page 2 of 24 · 468 trades